The Indian Council of Medical Research (ICMR) and Pune based National Institute of Virology (NIV) have joined forces with leading vaccine manufacturer Bharat Biotech International Limited (BBIL) to develop an indigenous vaccine effective against COVID-19 disease, reports Times of India.
The combine would together use the strain of COVID-19 virus which was successfully isolated by NIV. The strain has already been transferred from NIV to BBIL's facility in Hyderabad which is the only company in the developing world to boast of having a biosafety level-3.
BBIL is known for having developed 10 different viral vaccines and has in the past delivered over five billion doses of these.
Recently, BBIL has also received the approval from the Council of Scientific and Industrial Research (CSIR) to develop human monoclonal antibodies to treat COVID-19 which would facilitate therapeutic treatment of COVID-19 wherein the antibodies developed would bind themselves to the virus cells and neutralise them.
BBIL's chairman and managing director Dr Krishna Ella has expressed pride in the company's partnership with ICMR and NIV in this project of national importance and said, "We will do everything to make this programme successful in our national endeavour to combat COVID-19 pandemic."
As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.
Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.
We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.
Becoming a Patron or a subscriber for as little as Rs 1200/year is the best way you can support our efforts.